Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Meningitis Mass Vaccination Sees Cases Drop 94%

Published: Monday, September 16, 2013
Last Updated: Monday, September 16, 2013
Bookmark and Share
A mass vaccination campaign in Chad in 2011 reduced all cases of meningitis by 94% and saw no cases of serogroup A meningococcal meningitis detected in 2012.

The finding comes from an evaluation by an international team including Oxford University scientists and led by the London School of Hygiene & Tropical Medicine and Centre de Support en Santé Internationale (CSSI) in Chad.

Several groups of bacteria can cause meningitis, the most important being meningococcus, which can trigger inflammation around the brain and spinal cord leading to disabilities such as deafness, paralysis, or death. The team looked at how a vaccine targeting serogroup A, the most common meningococci group in sub-Saharan Africa, affected both cases of infection and the number of people carrying the disease – carriers, who can transmit the infection through coughing and sneezing, can be detected by analysing throat swabs.

Approximately 1.8 million people aged 1-29 years received a single dose of PsA-TT (also known as MenAfriVac ®) in three regions of Chad in December 2011. The incidence of meningitis of any kind in these regions during the 2012 meningitis season was 2.5 per 100,000 people, compared to an incidence of 43.6 per 100,000 in regions where mass vaccination had not been undertaken – a 94% drop in the incidence of meningitis. No cases of serogroup A meningococcal meningitis were detected in the three vaccinated regions.

Oxford University researchers, led by Professor Martin Maiden in the Department of Zoology, played a key role in the research by designing and leading the molecular characterisation of the bacterial specimens for the study. This involved developing and applying new genome-based approaches for identifying disease-associated and harmless meningococci present in throat swab samples.

'These approaches had to be rapid and precise yet inexpensive and were applied in Oxford to thousands of specimens collected in Chad,' said Professor Maiden. 'Our results demonstrate the effectiveness of the vaccine in halting a large epidemic in Chad and shows that the vaccine worked by preventing the transmission of the epidemic strain among healthy carriers. These findings will be valuable in designing vaccination programmes aimed at eliminating group A meningococcal disease from the "meningitis belt" of Africa.'

Professor Sir Brian Greenwood from the London School of Hygiene & Tropical Medicine, lead author of the study, said: 'This is one of the most dramatic outcomes from a public health intervention that I have seen during a long career of research in Africa. There are now real prospects that the devastating effects of this infection in Africa can be prevented.'


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
Thursday, July 16, 2015
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
Wednesday, January 07, 2015
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Friday, November 07, 2014
New Foot-and-Mouth Vaccine is Safer and Cheaper to Produce
A new vaccine against foot-and-mouth disease that is safer to produce and easier to store has been developed by scientists from the University of Oxford and The Pirbright Institute.
Thursday, March 28, 2013
Oxford's Role in New Meningitis Vaccine
EMA recommends Novartis' Bexero (MenB) vaccine to protect children against meningitis B.
Thursday, November 22, 2012
First Trial of a New Hepatitis C Vaccine Shows Promise
A new vaccine against the chronic liver disease hepatitis C has shown promising results in a first clinical trial in humans, Oxford University researchers report.
Thursday, January 05, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!